A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes

Cell Signal. 2014 Jun;26(6):1355-68. doi: 10.1016/j.cellsig.2014.02.015. Epub 2014 Feb 28.

Abstract

Insulin-induced insulin receptor (IR) tyrosine kinase activation and insulin cell survival responses have been reported to be under the regulation of a membrane associated mammalian neuraminidase-1 (Neu1). The molecular mechanism(s) behind this process is unknown. Here, we uncover a novel Neu1 and matrix metalloproteinase-9 (MMP-9) cross-talk in alliance with neuromedin B G-protein coupled receptor (GPCR), which is essential for insulin-induced IR activation and cellular signaling. Neu1, MMP-9 and neuromedin B GPCR form a complex with IRβ subunit on the cell surface. Oseltamivir phosphate (Tamiflu®), anti-Neu1 antibodies, broad range MMP inhibitors piperazine and galardin (GM6001), MMP-9 specific inhibitor (MMP-9i), and GPCR neuromedin B specific antagonist BIM-23127 dose-dependently inhibited Neu1 activity associated with insulin stimulated rat hepatoma cells (HTCs) that overly express human IRs (HTC-IR). Tamiflu, anti-Neu1 antibodies and MMP-9i attenuated phosphorylation of IRβ and insulin receptor substrate-1 (IRS1) associated with insulin-stimulated cells. Olanzapine, an antipsychotic agent associated with insulin resistance, induced Neu3 sialidase activity in WG544 or 1140F01 human sialidosis fibroblast cells genetically defective in Neu1. Neu3 antagonist 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) and anti-Neu3 antibodies inhibited sialidase activity associated with olanzapine treated murine Neu4 knockout macrophage cells. Olanzapine attenuated phosphorylation of IGF-R and IRS1 associated with insulin-stimulated human wild-type fibroblast cells. Our findings identify a novel insulin receptor-signaling platform that is critically essential for insulin-induced IRβ tyrosine kinase activation and cellular signaling. Olanzapine-induced Neu3 sialidase activity attenuated insulin-induced IGF-R and IRS1 phosphorylation contributing to insulin resistance.

Keywords: Insulin receptor; Matrix metalloproteinase-9; Neuraminidase-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antipsychotic Agents / pharmacology
  • Benzodiazepines / pharmacology
  • Cell Line, Tumor
  • Diabetes Mellitus, Type 2 / metabolism*
  • Humans
  • Insulin / physiology
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin Resistance*
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Neuraminidase / metabolism*
  • Olanzapine
  • Phosphorylation
  • Protein Processing, Post-Translational
  • Protein Transport
  • Rats
  • Receptor, IGF Type 1 / metabolism
  • Receptor, Insulin / metabolism*
  • Signal Transduction*

Substances

  • Antipsychotic Agents
  • IRS1 protein, human
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Benzodiazepines
  • Receptor, IGF Type 1
  • Receptor, Insulin
  • NEU1 protein, human
  • Neu3 protein, human
  • Neuraminidase
  • MMP9 protein, human
  • Matrix Metalloproteinase 9
  • Olanzapine